Alliance Wealth Advisors LLC UT Has $4.19 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Alliance Wealth Advisors LLC UT raised its stake in Eli Lilly and Company (NYSE:LLY) by 31.9% during the 1st quarter, Holdings Channel reports. The institutional investor owned 5,078 shares of the company’s stock after purchasing an additional 1,228 shares during the quarter. Eli Lilly and Company makes up 1.1% of Alliance Wealth Advisors LLC UT’s holdings, making the stock its 19th largest position. Alliance Wealth Advisors LLC UT’s holdings in Eli Lilly and Company were worth $4,194,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in LLY. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after buying an additional 21 shares during the period. Citizens National Bank Trust Department grew its position in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. bought a new stake in Eli Lilly and Company in the first quarter worth approximately $40,000. Mascagni Wealth Management Inc. bought a new stake in Eli Lilly and Company in the fourth quarter worth approximately $43,000. Finally, O Brien Wealth Partners LLC grew its position in Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after acquiring an additional 12 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity

In related news, CEO David A. Ricks bought 1,632 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on LLY. UBS Group decreased their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Erste Group Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. Morgan Stanley reissued an “overweight” rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Finally, Leerink Partners reissued a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $964.88.

Eli Lilly and Company Price Performance

NYSE LLY opened at $701.51 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a fifty day simple moving average of $764.55 and a 200 day simple moving average of $794.69. The company has a market cap of $663.95 billion, a P/E ratio of 45.85, a P/E/G ratio of 0.95 and a beta of 0.44. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the company earned $3.92 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.